<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><description>聚焦医药投研</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 16 Apr 2021 19:18:53 +0800</pubDate><image><url>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</url><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>Claudin18.2靶点引发国内创新药企内卷大战</title><link>https://mp.weixin.qq.com/s/z7UwFAXS-3Dw5Rk-I1rOsw</link><description></description><content:encoded><![CDATA[Claudin18.2靶点引发国内创新药企内卷大战]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:12:25 +0800</pubDate></item><item><title>mRNA疫苗好，国内企业递送技术如何？</title><link>https://mp.weixin.qq.com/s/rnqK4LN-qjVT_9F0a2vZSQ</link><description></description><content:encoded><![CDATA[mRNA疫苗好，国内企业递送技术如何？]]></content:encoded><pubDate>Wed, 14 Apr 2021 11:06:34 +0800</pubDate></item><item><title>Achilles公司开发TIL+新生抗原治疗实体瘤，市值6亿美元</title><link>https://mp.weixin.qq.com/s/ItWKnSEcqGGj6ENcYne2sA</link><description></description><content:encoded><![CDATA[Achilles公司开发TIL+新生抗原治疗实体瘤，市值6亿美元]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:36:44 +0800</pubDate></item><item><title>中国biotech如何做License-in？</title><link>https://mp.weixin.qq.com/s/pc8G_kGLZqol8DNwXpyN_g</link><description></description><content:encoded><![CDATA[中国biotech如何做License-in？]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:12:19 +0800</pubDate></item><item><title>Instil公司开发TIL细胞疗法治疗实体瘤，市值30亿美元</title><link>https://mp.weixin.qq.com/s/wWYc-qoe7hVzoCAOx6l6sQ</link><description></description><content:encoded><![CDATA[Instil公司开发TIL细胞疗法治疗实体瘤，市值30亿美元]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:29:37 +0800</pubDate></item><item><title>TCR-T治疗实体瘤的“成功模式”</title><link>https://mp.weixin.qq.com/s/9D3YOpDrIavW5_YCMXIEGA</link><description></description><content:encoded><![CDATA[TCR-T治疗实体瘤的“成功模式”]]></content:encoded><pubDate>Fri, 02 Apr 2021 13:55:38 +0800</pubDate></item><item><title>别构调节剂让小分子药物迎来第二春</title><link>https://mp.weixin.qq.com/s/dXf46aD0j5iQF7A485wZrw</link><description></description><content:encoded><![CDATA[别构调节剂让小分子药物迎来第二春]]></content:encoded><pubDate>Fri, 26 Mar 2021 11:12:57 +0800</pubDate></item><item><title>半年溢价5倍，迪哲医药是如何打造差异化药物的</title><link>https://mp.weixin.qq.com/s/peKXerT-VngrKQO9lFLKwA</link><description></description><content:encoded><![CDATA[半年溢价5倍，迪哲医药是如何打造差异化药物的]]></content:encoded><pubDate>Thu, 25 Mar 2021 17:48:57 +0800</pubDate></item><item><title>BTK抑制剂全球市场分析</title><link>https://mp.weixin.qq.com/s/VTCoLAHQdBXNgehzQQ0ZHg</link><description></description><content:encoded><![CDATA[BTK抑制剂全球市场分析]]></content:encoded><pubDate>Fri, 19 Mar 2021 16:43:31 +0800</pubDate></item><item><title>现在投资mRNA疫苗核心递送技术晚了吗？——肿瘤篇</title><link>https://mp.weixin.qq.com/s/3UZKmcnHIofLda8oRaEQWQ</link><description></description><content:encoded><![CDATA[现在投资mRNA疫苗核心递送技术晚了吗？——肿瘤篇]]></content:encoded><pubDate>Wed, 17 Mar 2021 16:13:28 +0800</pubDate></item></channel></rss>